Abstract 3474
Background
Adoptive cell therapy (ACT) of expanded in-vitro tumour specific T-cells isolated from fresh tumour infiltrates has shown promising results in melanoma patients, and in ovarian cancer (OC). The use of pre-enriched tumor-specific T cells may simplify the TIL production method and enhances the tumour-reactivity of the final cellular product. We have investigated the role of PD-1 as a biomarker for the isolation and expansion of tumour-specific CD8 TILs in OC.
Methods
Samples from ten OC patients were analyzed. We used flow cytometry FACs Aria sorter for phenotyping and separate T-cells. For reactivity assay we performed co-cultures of TILs with autologous tumour and non-related tumor cell line, and measured INFγ released by ELISPOT. For immunofluorescence multiplex we used a Vectra® microscope and inForm® software to analyzed data. Tumour DNA sequencing was done using a TrueShight™ 170 gene panel.
Results
Both CD8+PD-1+and CD8+PD-1- TIL subsets expanded efficiently and no difference in fold expansion was found. Tumor-reactive TILs were detected in 5/10 patients and this tumor-reactivity was exclusively present in the cells derived from the PD-1+-enriched fraction. There were a higher frequency of CD8+PD-1+CD137+ by FC (p = 0,0079) in reactive group in fresh biopsy. Total CD8+and CD8+PD-1+were more frequent in reactive patients (p = 0,0079, p = 0,0317). CD8+PD-1+CD137+were more frequent (p = 0,0437) by IF in the tumoral epithelium of reactive patients. There were more total CD4+ and CD4+PD-1+by FC in reactive group (p = 0,0079, p = 0,0159). By IF we observed more CD4+PD-1+in both epithelium and stroma of reactive group (p = 0,0437). Patients with reactive TILs exhibited significantly high number of missense mutactions (p = 0,0198).
Conclusions
CD8+PD-1+ T-cell subset include tumour-specific T-cell in OC. CD8+PD-1+CD137+ cells in epithelium may work as a biomarker for reactivity. Higher mutation load is related with tumour-reactive TILs in OC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
ISCIII Spanish grant (PI15/02027).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1109 - First Canadian Interim Analysis from the Phase IIIb CompLEEment-1 Ribociclib + Letrozole HR+ HER2- Advanced Breast Cancer Trial
Presenter: Cristiano Ferrario
Session: Poster Display session 2
Resources:
Abstract
4401 - Real-world effectiveness of first-line palbociclib + letrozole for metastatic breast cancer 4 years post approval in the US
Presenter: Jonathan Kish
Session: Poster Display session 2
Resources:
Abstract
5876 - Palbociclib-Fulvestrant (PALBO-FUL) and Everolimus -Exemestane (EVE-EXE) for Second line Hormonal Treatment (HT) of Metastatic Breast Cancer (MBC) with Lobular Histology: a Propensity Score Matched Analysis of a Multicenter ‘Real-World’ Patients (pts) Series.
Presenter: Armando Orlandi
Session: Poster Display session 2
Resources:
Abstract
3587 - Dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in postmenopausal women with ER+/HER2- locally advanced or metastatic breast cancer (ABC)
Presenter: E Dees
Session: Poster Display session 2
Resources:
Abstract
5696 - Final results of the STEM trial: SFX-01 in the Treatment and Evaluation of ER+ Her2- Metastatic breast cancer (mBC)
Presenter: Sacha Howell
Session: Poster Display session 2
Resources:
Abstract
1475 - Alpelisib (ALP) + Fulvestrant (FUL) in Hormone-Receptor Positive (HR+), Human Epidermal Growth Factor Receptor-2–Negative (HER2–) Advanced Breast Cancer (ABC): Subgroup Analysis by Presence of Visceral Metastasis (VM) in the SOLAR-1 Trial
Presenter: Mario Campone
Session: Poster Display session 2
Resources:
Abstract
2549 - Phase 1 Dose Escalation Study of a Selective Androgen Receptor Modulator RAD140 in Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) Breast Cancer (BC)
Presenter: Erika Hamilton
Session: Poster Display session 2
Resources:
Abstract
3787 - A Phase I study of XZP-3287, a novel oral CDK4/6 Inhibitor, administered on a continuous dosing schedule, in patients with advanced solid tumours
Presenter: Binghe Xu
Session: Poster Display session 2
Resources:
Abstract
4835 - Phase-I dose-escalation and expansion study of the PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors
Presenter: Huiping Li
Session: Poster Display session 2
Resources:
Abstract
5083 - Phase 2 study of DHP107 (Liporaxel®, oral paclitaxel) in first-line, HER2 negative recurrent/metastatic breast cancer (OPTIMAL study, NCT03315364)
Presenter: Jin-Hee Ahn
Session: Poster Display session 2
Resources:
Abstract